Evidence map›Paper›PMID 30328622›Full record

ArticleEpilepsia2018

Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs.

Peter J West, Gerald W Saunders, Peggy Billingsley, Misty D Smith, H Steve White, Cameron S Metcalf, Karen S Wilcox

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. The Positive Allosteric Modulator ofThe Journal of pharmacology and experimental therapeutics · 2020
    Article
  15. Article
  16. The 4-Aminopyridine Model of Acute SeizuresFrontiers in neuroscience · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Peter J WestDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-5774-5180
Gerald W SaundersEpilepsy Therapy Screening Program (ETSP) Contract Site, University of Utah, Salt Lake City, Utah.
Peggy BillingsleyEpilepsy Therapy Screening Program (ETSP) Contract Site, University of Utah, Salt Lake City, Utah.
Misty D SmithDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
H Steve WhiteDepartment of Pharmacy, University of Washington, Seattle, Washington.
Cameron S MetcalfDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1510-0405
Karen S WilcoxDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah.
University of Utah · USUniversity of Washington · US

Funding

Intellectual and Developmental Disabilities Research CenterU54HD083091 · NICHD · UNIVERSITY OF WASHINGTON · PI DOHERTY, DANIEL · 2014 to 2019
$7.9M
NICHD NIH HHS U54 HD083091NINDS NIH HHS HHSN271201100029C
6 · The paper itself

Abstract

objectiveApproximately 30% of patients with epilepsy are refractory to existing antiseizure drugs (ASDs). Given that the properties of the central nervous systems of these patients are likely to be altered due to their epilepsy, tissues from rodents that have undergone epileptogenesis might provide a therapeutically relevant disease substrate for identifying compounds capable of attenuating pharmacoresistant seizures. To facilitate the development of such a model, this study describes the effects of classical glutamate receptor antagonists and 20 ASDs on recurrent epileptiform discharges (REDs) in brain slices derived from the kainate-induced status epilepticus model of temporal lobe epilepsy (KA-rats).

methodsHorizontal brain slices containing the medial entorhinal cortex (mEC) were prepared from KA-rats, and REDs were recorded from the superficial layers. 6-cyano-7-nitroquinoxaline-2,3-dione, (2R)-amino-5-phosphonovaleric acid, tetrodotoxin, or ASDs were bath applied for 20 minutes. Concentration-dependent effects and half maximal effective concentration values were determined for RED duration, frequency, and amplitude.

resultsASDs targeting sodium and potassium channels (carbamazepine, eslicarbazepine, ezogabine, lamotrigine, lacosamide, phenytoin, and rufinamide) attenuated REDs at concentrations near their average therapeutic plasma concentrations. γ-aminobutyric acid (GABA)ergic synaptic transmission-modulating ASDs (clobazam, midazolam, phenobarbital, stiripentol, tiagabine, and vigabatrin) attenuated REDs only at higher concentrations and, in some cases, prolonged RED durations. ASDs with other/mixed mechanisms of action (bumetanide, ethosuximide, felbamate, gabapentin, levetiracetam, topiramate, and valproate) and glutamate receptor antagonists weakly or incompletely inhibited RED frequency, increased RED duration, or had no significant effects. SIGNIFICANCE: Taken together, these data suggest that epileptiform activity recorded from the superficial layers of the mEC in slices obtained from KA-rats is differentially sensitive to existing ASDs. The different sensitivities of REDs to these ASDs may reflect persistent molecular, cellular, and/or network-level changes resulting from disease. These data are expected to serve as a foundation upon which future therapeutics may be differentiated and assessed for potentially translatable efficacy in patients with refractory epilepsy.

Indexed as

AnimalsAnticonvulsantsDisease Models, AnimalDose-Response Relationship, DrugElectric StimulationEntorhinal CortexEpilepsyExcitatory Amino Acid AgonistsExcitatory Postsynaptic PotentialsIn Vitro TechniquesKainic AcidMalePatch-Clamp TechniquesRatsRats, Sprague-DawleySodium Channel BlockersAnticonvulsantsExcitatory Amino Acid AgonistsKainic AcidSodium Channel BlockersTetrodotoxinantiepileptic drugsbrain slicespharmacoresistance

Identifiers

PMID30328622
PMCPMC6215509
OpenAlexW2896351911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.